MedPath

Assessing Treatment Outcomes for Intrabony Defects: Nanohydroxyapatite vs. Injectable Platelet-Rich Fibrin with or without Laser Therapy

Phase 4
Conditions
Health Condition 1: K053- Chronic periodontitis
Registration Number
CTRI/2024/01/061481
Lead Sponsor
ONE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

I. Patients of both sexes between 30 and 65 years of age with moderate

To severe generalized periodontitis.

Ii. Patients exhibiting atleast one intrabony defect with probing pocket

Depth = 5mm, radiographic defect on iopa of = 3mm and two or three

Walled defect in maxillary and mandibular posterior regions.

Iii. Patients exhibiting clinical attachment loss (cal) = 4 mm.

Iv. No history of intake of antibiotics or other medications affecting the

Periodontium in preceding 6 months.

V. Patient willing for surgery and ready to give written consent.

Exclusion Criteria

I. Systemic illness known to affect the outcomes of periodontal therapy

Ii. Smokers, pregnant/lactating patients & patients with malocclusion

Were excluded.

Iii. Teeth with endodontic (pulpal) involvement.

Iv. Patient on medication such as corticosteroids and calcium channel

Blockers.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical and radiographic evaluation of nanohydroxyapatite bone graft and injectable platelet rich fibrin with or without diode laser therapy for treatment of intrabony defectsTimepoint: baseline to 6 months
Secondary Outcome Measures
NameTimeMethod
oneTimepoint: None
© Copyright 2025. All Rights Reserved by MedPath